Guardion Health Sciences, Inc. (NASDAQ:GHSI) Short Interest Down 33.7% in June

Guardion Health Sciences, Inc. (NASDAQ:GHSI) was the recipient of a significant decline in short interest in June. As of June 15th, there was short interest totalling 97,300 shares, a decline of 33.7% from the May 31st total of 146,800 shares. Approximately 9.5% of the company’s stock are short sold. Based on an average daily volume of 9,100 shares, the short-interest ratio is presently 10.7 days.

Guardion Health Sciences Stock Performance

Shares of NASDAQ:GHSI traded up $0.13 during trading on Friday, hitting $10.04. The company’s stock had a trading volume of 1,124 shares, compared to its average volume of 6,173. The company has a market capitalization of $12.84 million, a PE ratio of -2.51 and a beta of 0.83. Guardion Health Sciences has a fifty-two week low of $5.01 and a fifty-two week high of $10.75. The business has a 50 day moving average price of $9.05 and a two-hundred day moving average price of $7.86.

Guardion Health Sciences (NASDAQ:GHSI) last posted its quarterly earnings results on Monday, May 13th. The company reported ($3.71) earnings per share (EPS) for the quarter. The company had revenue of $3.00 million during the quarter. Guardion Health Sciences had a negative net margin of 16.69% and a negative return on equity of 77.29%.

Guardion Health Sciences Company Profile

Guardion Health Sciences, Inc, a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment.